Table 4. Neutralising antibody response 21 days after one and two injections, 21 days apart of adjuvanted or non-adjuvanted H5N1 vaccine.
| Age and vaccine formulation group: dose and adjuvant content | ||||||||
| 9 to 17 years | 3 to 8 years | 6 to 35 months | ||||||
| 30 µg+Al | 7.5 µg | 30 µg+Al | 7.5 µg | 30 µg+Al | 15 µg+Al | 7.5 µg | 3.8 µg | |
| After 1st vaccination (Day 21) | ||||||||
| GMT (95%CI) | 11.8 (6.95; 20.2) | 7.26 (5.34; 9.87) | 7.40 (5.09; 10.7) | 7.69 (5.36; 11.0) | 5.28 (4.72; 5.91) | 5.82 (4.58; 7.38) | 6.19 (4.48; 8.57) | 6.75 (5.04; 9.04) |
| After 2nd vaccination (Day 42) | ||||||||
| GMT (95%CI) | 92.1 (61.6; 138) | 33.5 (22.9; 49.0) | 106 (84.6; 133) | 54.2 (35.3; 83.1) | 72.1 (49.1; 106) | 60.2 (36.2; 100) | 40.7 (25.0; 66.3) | 30.4 (18.6; 49.5) |
| n/N (%) 2-fold increase day 0–42 | 29/30 (97) | 27/30 (90) | 30/30 (100) | 29/29 (97) | 29/30 (97) | 28/30 (93) | 25/30 (83) | 24/30 (80) |
| n/N (%) 4-fold increase day 0–42 | 29/30 (97) | 20/30 (67) | 30/30 (100) | 21/29 (72) | 27/30 (90) | 25/30 (83) | 21/30 (70) | 18 (60) |
N is the number of participants in each group for whom data are available at each timepoint necessary to calculate each table entry.